Lexaria Bioscience Corp. (NASDAQ: LEXX) announced an extension of its Material Transfer Agreement (MTA) with an undisclosed pharmaceutical company, referred to as PharmaCO, to continue evaluating Lexaria’s DehydraTECH™ technology for oral drug delivery. Originally signed on August 30, 2024, the MTA has been extended through December 31, 2026, to allow PharmaCO to receive and review Lexaria’s 2026 research and development results related to GLP-1 drugs. The extension keeps a temporary exclusive license active and enables further strategic planning discussions with PharmaCO’s human clinical and business development teams.
This development is significant as it signals sustained interest from a major pharmaceutical partner in Lexaria’s DehydraTECH platform, which has shown promise in improving oral bioavailability of drugs, particularly for GLP-1 receptor agonists used in treating diabetes and obesity. Over the past 12 months, Lexaria has advanced its GLP-1 program with studies including Human Study #7, Animal Study #1, and Animal Study #2, all fully funded and expected to yield results in the third and fourth quarters of 2026. These studies aim to provide evidence to support further collaboration and potential licensing of Lexaria’s technology.
The extended agreement allows PharmaCO to assess Lexaria’s latest data before making decisions on broader partnerships. For Lexaria, this continued relationship validates its technology and could lead to revenue-generating licensing deals. The company’s DehydraTECH platform has repeatedly demonstrated the ability to increase drug absorption, reduce side effects, and enhance delivery across the blood-brain barrier. Lexaria holds 65 granted patents and operates a licensed in-house research laboratory.
Investors should note that the extension provides a clearer timeline for potential commercialization, though risks remain, including regulatory hurdles and scientific uncertainties. The company’s forward-looking statements caution that actual results may differ due to factors such as competition, regulatory approvals, and research outcomes. Lexaria’s stock (NASDAQ: LEXX) may see volatility as results from upcoming studies are released. The full press release is available at NewMediaWire.
For more information about Lexaria and its technology, visit Lexaria Bioscience.
